XORTX Awaits ASX Approval to Close Acquisition of Renal Anti-Fibrotic Program from Vectus
I'm PortAI, I can summarize articles.
XORTX Therapeutics Inc. is awaiting approval from the Australian Securities Exchange to finalize its acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited. The decision on whether shareholder approval is needed for the sale of the VB4-P5 intellectual property is pending. The acquisition is scheduled to close by January 13, 2026, with both companies committed to completing the deal and providing updates once approval is clarified.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments